{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["37(10)"],"submitter":["Augello M"],"pubmed_abstract":["<h4>Objective</h4>Immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccines in people with HIV (PWH) with a history of late presentation (LP) and their durability have not been fully characterized.<h4>Design</h4>In this prospective, longitudinal study, we sought to assess T-cell and humoral responses to SARS-CoV-2 mRNA vaccination up to 6 months in LP-PWH on effective combination antiretroviral therapy (cART) as compared to HIV-negative healthcare workers (HCWs), and to evaluate whether previous SARS-CoV-2 infection modulates immune responses to vaccine.<h4>Methods</h4>SARS-CoV-2 spike (S)-specific T-cell responses were determined by two complementary flow cytometry methodologies, namely activation-induced marker (AIM) assay and intracellular cytokine s"],"journal":["AIDS (London, England)"],"pagination":["1503-1517"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10355808"],"repository":["biostudies-literature"],"pubmed_title":["Six-month immune responses to mRNA-1273 vaccine in combination antiretroviral therapy treated late presenter people with HIV according to previous SARS-CoV-2 infection."],"pmcid":["PMC10355808"],"pubmed_authors":["Rovito R","Augello M","Tincati C","d'Arminio Monforte A","Bono V","Marchetti G"],"additional_accession":[]},"is_claimable":false,"name":"Six-month immune responses to mRNA-1273 vaccine in combination antiretroviral therapy treated late presenter people with HIV according to previous SARS-CoV-2 infection.","description":"<h4>Objective</h4>Immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccines in people with HIV (PWH) with a history of late presentation (LP) and their durability have not been fully characterized.<h4>Design</h4>In this prospective, longitudinal study, we sought to assess T-cell and humoral responses to SARS-CoV-2 mRNA vaccination up to 6 months in LP-PWH on effective combination antiretroviral therapy (cART) as compared to HIV-negative healthcare workers (HCWs), and to evaluate whether previous SARS-CoV-2 infection modulates immune responses to vaccine.<h4>Methods</h4>SARS-CoV-2 spike (S)-specific T-cell responses were determined by two complementary flow cytometry methodologies, namely activation-induced marker (AIM) assay and intracellular cytokine s","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Aug","modification":"2026-03-18T14:09:18.977Z","creation":"2025-04-04T22:47:37.729Z"},"accession":"S-EPMC10355808","cross_references":{"pubmed":["37199415"],"doi":["10.1097/QAD.0000000000003585"]}}